U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Axicabtagene Ciloleucel (Yescarta): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy [Internet].

Axicabtagene Ciloleucel (Yescarta): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...